BLUEJAY DIAGNOSTICS INC (BJDX)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$0.83-1.94%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Broken: Primary pillar broken — Manage cash burn and operating losses near recent levels: metric not reported.
Bluejay aims to raise $20 million by end of 2027. It has a deal to improve manufacturing. The company is working to reduce cash losses but still spends more than it earns.
Bluejay keeps losing money and burning cash. It needs more capital soon. The recent stock selloff shows investors doubt its recovery.
The market prices in a big decline in growth over 3 to 5 years. Our fair value is $10, reflecting the high risk and ongoing losses. We see no clear signs of a turnaround yet.
Breaks if: fails to raise at least $20 million by end of 2027
Secure additional capital funding to support operations through 2027 and beyond FDA submission and commercialization.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and faces high risks, but it is focused on advancing its regulatory submissions and expanding manufacturing capabilities.
The market appears to have priced in a low valuation compared to peers, reflecting skepticism about BJDX's ability to improve its financial performance. There is a divergence in expectations, as the company is seen as cheap relative to its industry.
Fundamentals are likely to remain weak in the near term, as there is an elevated risk of missing earnings expectations. Management is making progress on key priorities, but the overall financial performance has not met industry standards.
The long-term thesis hinges on management's ability to advance regulatory submissions and secure necessary capital. Additionally, the performance of larger healthcare companies could influence sentiment and momentum in the sector.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 2 quarters including 2026-Q1 and 2026-Q2. Management expects to raise at least $20 million of further capital through the end of 2027 fiscal year and recent financing increased cash to $9.6 million at 2026-Q2, with cash runway estimated through 2027-Q2. The trajectory shows delivering capital raises and maintaining runway consistent with stated goals.
“Recent financing provides additional resources; cash runway estimated through second quarter of 2027.”
“Company expects to raise at least $20 million of further capital through end of 2027 fiscal year.”
Breaks if: manufacturing ramp with Argonaut fails or delays significantly
Breaks if: operating income or net income worsens beyond recent levels
Maintain financial discipline to control operating losses and cash burn while advancing clinical and regulatory programs.
Stated as a priority in 6 quarters from 2025-Q1 through 2026-Q2. Operating income remained negative, ranging from -$1.99M in 2025-Q2 to -$2.35M in 2026-Q2, with net income similarly negative. Management states financial discipline in managing expenses while advancing programs. The trajectory shows persistent operating losses with limited improvement, indicating ongoing challenge in managing cash burn.
“Company ended quarter with $9.6 million cash following significant financing.”
“Company believes it has managed operating expenses with financial discipline.”
“Operating income was negative $1.46 million.”
“Operating income was negative $1.62 million.”
“Operating income was negative $1.99 million.”
“Operating income was negative $1.89 million.”
In the next 1 to 3 years, BJDX's success will depend on its operational execution and external market conditions. Not investment advice.